Quest Diagnostics Added as Short Idea by Hedgeye with 20% Downside Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy DGX?
Source: seekingalpha
- Short Idea Shift: Hedgeye has added Quest Diagnostics (DGX) as a new short idea, projecting a downside potential of 20%, reflecting analysts' concerns about the company's future growth, particularly facing tough comps in Q2 2026.
- Growth Deceleration Outlook: Analyst Tom Tobin noted that while management's guidance for Q1 2026 aligns with expectations, the market still models approximately 4% growth and margin expansion, which may be overly optimistic as growth normalizes sooner than anticipated.
- Valuation Pressure: Despite Quest Diagnostics' elevated valuation of 12.2x EV/EBITDA compared to the industry average of 10.7x, analysts believe there is up to a 20% downside risk, especially if estimates are cut due to decelerating growth.
- Key Catalysts: Future key catalysts include Q2 2026 performance, a reset of 2027 guidance, and any slowdown in partnership channels, all of which will directly impact the company's market performance and investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to fall
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 204.000
Low
190.00
Averages
203.33
High
210.00
Current: 204.000
Low
190.00
Averages
203.33
High
210.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quest Diagnostics Reports Strong Q1 2026 Earnings, Raises Full-Year Outlook
- Strong Financial Performance: Quest Diagnostics reported Q1 2026 revenue of $2.9 billion, reflecting approximately 9% year-over-year growth, exceeding consensus estimates by $60 million, indicating robust demand in its diagnostic information services segment.
- Earnings Per Share Growth: The adjusted diluted EPS for the quarter reached $2.52, marking a 13% year-over-year increase and surpassing estimates by $0.13, which highlights an improvement in adjusted operating income margin by 10 basis points to 15.4% compared to the prior year.
- Upgraded Full-Year Guidance: Following the strong Q1 results, Quest raised its full-year revenue outlook to between $11.78 billion and $11.90 billion, with adjusted diluted EPS expectations of $10.63 to $10.83, both exceeding consensus estimates at the midpoint.
- Positive Future Outlook: Earlier in the year, Quest had projected revenue of $11.70 billion to $11.82 billion for 2026, and the recent upward revision reflects the company's confidence in sustained growth, particularly as demand for diagnostic services continues to rise.
See More
Quest Diagnostics Added as Short Idea by Hedgeye with 20% Downside Potential
- Short Idea Shift: Hedgeye has added Quest Diagnostics (DGX) as a new short idea, projecting a downside potential of 20%, reflecting analysts' concerns about the company's future growth, particularly facing tough comps in Q2 2026.
- Growth Deceleration Outlook: Analyst Tom Tobin noted that while management's guidance for Q1 2026 aligns with expectations, the market still models approximately 4% growth and margin expansion, which may be overly optimistic as growth normalizes sooner than anticipated.
- Valuation Pressure: Despite Quest Diagnostics' elevated valuation of 12.2x EV/EBITDA compared to the industry average of 10.7x, analysts believe there is up to a 20% downside risk, especially if estimates are cut due to decelerating growth.
- Key Catalysts: Future key catalysts include Q2 2026 performance, a reset of 2027 guidance, and any slowdown in partnership channels, all of which will directly impact the company's market performance and investor confidence.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
US Stocks Close Lower as Oil Prices Rebound Impact Market
- Market Decline: The S&P 500 index fell by 0.63%, the Dow Jones Industrial Average dropped by 0.59%, and the Nasdaq 100 index decreased by 0.42%, reflecting investor concerns over the uncertainty surrounding Iran's geopolitical situation, which dampened market sentiment.
- Oil Price Rebound Impact: WTI crude oil prices rebounded by over 2% after Iran announced it would not attend peace talks, raising fears of a deepening global energy crisis, which could further hinder economic recovery.
- Supportive Economic Data: March retail sales rose by 1.7% month-over-month, surpassing expectations of 1.4%, indicating robust consumer spending that may provide some support for the stock market, despite overall market pressures.
- Fed Nominee Supports Independence: Fed Chair nominee Kevin Warsh emphasized the importance of monetary policy independence and controlling inflation in his Senate Banking Committee statement, which could positively influence market confidence.
See More
Significant Stock Movements for Multiple Companies
- Valmont Industries Strong Performance: The agricultural products and infrastructure company saw its stock rise 12% after reporting better-than-expected first-quarter results, driven by strong demand in its North American utility business, while also raising the lower end of its full-year earnings guidance, indicating market confidence in future growth.
- Pitney Bowes Revenue Beat: Mailing equipment and services giant Pitney Bowes reported first-quarter revenue of $477 million, exceeding the market consensus of $465.9 million, leading to an 8% stock increase, which reflects the company's solid performance in a competitive market.
- UnitedHealth Earnings Surprise: UnitedHealth reported first-quarter earnings of $7.23 per share and revenue of $11.72 billion, both surpassing analyst expectations, resulting in a 9% stock increase, while the company also raised its full-year earnings outlook, showcasing its strong market position.
- Quest Diagnostics Strong Results: Laboratory testing services company Quest Diagnostics posted first-quarter earnings of $2.50 per share, exceeding the expected $2.37, with revenue reaching $2.90 billion, surpassing the $2.83 billion consensus estimate, leading to a 5.2% stock increase, highlighting its competitive edge in the industry.
See More
Quest Diagnostics Reports Strong Q1 2026 Earnings, Raises Full-Year Outlook
- Strong Financial Performance: Quest Diagnostics reported Q1 2026 revenue of $2.9 billion, reflecting approximately 9% year-over-year growth, exceeding consensus estimates by $60 million, indicating robust demand in its diagnostic information services segment.
- Earnings Per Share Growth: The adjusted diluted EPS for the quarter reached $2.52, marking a 13% year-over-year increase and surpassing estimates by $0.13, which highlights an improvement in adjusted operating income margin by 10 basis points to 15.4% compared to the prior year.
- Upgraded Full-Year Guidance: Following the strong Q1 results, Quest raised its full-year revenue outlook to between $11.78 billion and $11.90 billion, with adjusted diluted EPS expectations of $10.63 to $10.83, both exceeding consensus estimates at the midpoint.
- Positive Future Outlook: Earlier in the year, Quest had projected revenue of $11.70 billion to $11.82 billion for 2026, and the recent upward revision reflects the company's confidence in sustained growth, particularly as demand for diagnostic services continues to rise.
See More
Quest Diagnostics Added as Short Idea by Hedgeye with 20% Downside Potential
- Short Idea Shift: Hedgeye has added Quest Diagnostics (DGX) as a new short idea, projecting a downside potential of 20%, reflecting analysts' concerns about the company's future growth, particularly facing tough comps in Q2 2026.
- Growth Deceleration Outlook: Analyst Tom Tobin noted that while management's guidance for Q1 2026 aligns with expectations, the market still models approximately 4% growth and margin expansion, which may be overly optimistic as growth normalizes sooner than anticipated.
- Valuation Pressure: Despite Quest Diagnostics' elevated valuation of 12.2x EV/EBITDA compared to the industry average of 10.7x, analysts believe there is up to a 20% downside risk, especially if estimates are cut due to decelerating growth.
- Key Catalysts: Future key catalysts include Q2 2026 performance, a reset of 2027 guidance, and any slowdown in partnership channels, all of which will directly impact the company's market performance and investor confidence.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
US Stocks Close Lower as Oil Prices Rebound Impact Market
- Market Decline: The S&P 500 index fell by 0.63%, the Dow Jones Industrial Average dropped by 0.59%, and the Nasdaq 100 index decreased by 0.42%, reflecting investor concerns over the uncertainty surrounding Iran's geopolitical situation, which dampened market sentiment.
- Oil Price Rebound Impact: WTI crude oil prices rebounded by over 2% after Iran announced it would not attend peace talks, raising fears of a deepening global energy crisis, which could further hinder economic recovery.
- Supportive Economic Data: March retail sales rose by 1.7% month-over-month, surpassing expectations of 1.4%, indicating robust consumer spending that may provide some support for the stock market, despite overall market pressures.
- Fed Nominee Supports Independence: Fed Chair nominee Kevin Warsh emphasized the importance of monetary policy independence and controlling inflation in his Senate Banking Committee statement, which could positively influence market confidence.
See More
Significant Stock Movements for Multiple Companies
- Valmont Industries Strong Performance: The agricultural products and infrastructure company saw its stock rise 12% after reporting better-than-expected first-quarter results, driven by strong demand in its North American utility business, while also raising the lower end of its full-year earnings guidance, indicating market confidence in future growth.
- Pitney Bowes Revenue Beat: Mailing equipment and services giant Pitney Bowes reported first-quarter revenue of $477 million, exceeding the market consensus of $465.9 million, leading to an 8% stock increase, which reflects the company's solid performance in a competitive market.
- UnitedHealth Earnings Surprise: UnitedHealth reported first-quarter earnings of $7.23 per share and revenue of $11.72 billion, both surpassing analyst expectations, resulting in a 9% stock increase, while the company also raised its full-year earnings outlook, showcasing its strong market position.
- Quest Diagnostics Strong Results: Laboratory testing services company Quest Diagnostics posted first-quarter earnings of $2.50 per share, exceeding the expected $2.37, with revenue reaching $2.90 billion, surpassing the $2.83 billion consensus estimate, leading to a 5.2% stock increase, highlighting its competitive edge in the industry.
See More
